PT  - JOURNAL ARTICLE
AU  - Salvatore Cazzato
AU  - Alessia Omenetti
AU  - Claudia Ravaglia
AU  - Venerino Poletti
TI  - Lung involvement in monogenic interferonopathies
AID  - 10.1183/16000617.0001-2020
DP  - 2020 Dec 31
TA  - European Respiratory Review
PG  - 200001
VI  - 29
IP  - 158
4099  - http://err.ersjournals.com/content/29/158/200001.short
4100  - http://err.ersjournals.com/content/29/158/200001.full
SO  - EUROPEAN RESPIRATORY REVIEW2020 Dec 31; 29
AB  - Monogenic type I interferonopathies are inherited heterogeneous disorders characterised by early onset of systemic and organ specific inflammation, associated with constitutive activation of type I interferons (IFNs). In the last few years, several clinical reports identified the lung as one of the key target organs of IFN-mediated inflammation. The major pulmonary patterns described comprise children's interstitial lung diseases (including diffuse alveolar haemorrhages) and pulmonary arterial hypertension but diagnosis may be challenging. Respiratory symptoms may be either mild or absent at disease onset and variably associated with systemic or organ specific inflammation. In addition, associated extrapulmonary clinical features may precede lung function impairment by years, and patients may display severe/endstage lung involvement, although this may be clinically hidden during the long-term disease course. Conversely, a few cases of atypical severe lung involvement at onset have been reported without clinically manifested extrapulmonary signs. Hence, a multidisciplinary approach involving pulmonologists, paediatricians and rheumatologists should always be considered when a monogenic interferonopathy is suspected. Pulmonologists should also be aware of the main pattern of presentation to allow prompt diagnosis and a targeted therapeutic strategy. In this regard, promising therapeutic strategies rely on Janus kinase-1/2 (JAK-1/2) inhibitors blocking the type I IFN-mediated intracellular cascade.Progressive severe lung impairment may occur clinically hidden during monogenic interferonopathies. Pulmonologists should be aware of the main patterns of presentation in order to allow prompt diagnosis and initiate targeted therapeutic strategy. https://bit.ly/2UeAeLn